Federal Register / Vol. 89, No. 182 / Thursday, September 19, 2024 / Notices 76863 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–480– 

1953, steve.britt@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders B Study Section. 

Date: October 24–25, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: InterContinental Chicago Hotel, 505 

North Michigan Avenue, Chicago, IL 60611 

(In-person and Virtual Meeting). 

Contact Person: Joel A. Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–496– 

9223, joel.saydoff@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders A Study Section. 

Date: October 21–22, 2024. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave. NW, Washington, DC 20037 (In-person 

and Virtual Meeting). 

Contact Person: Natalia Strunnikova, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, NINDS/NIH/DHHS, NSC, 6001 

Executive Boulevard, Rockville, MD 20852, 

301–402–0288, natalia.strunnikova@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; HEAL Initiative: Nonaddictive Analgesic Therapeutics 

Development to Treat Pain. 

Date: October 17, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: W. Ernest Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–496– 

4056, lyonse@ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS). 

Dated: September 13, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–21385 Filed 9–18–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Diabetes, 

Endocrinology and Metabolic Diseases B 

Study Section. 

Date: October 23–25, 2024. 

Time: 10:00 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Charlene J. Repique, Ph.D., 

Scientific Review Officer, National Institute 

of Diabetes and Digestive and Kidney 

Diseases, National Institutes of Health, 6707 

Democracy Boulevard, Rm 7347, Bethesda, 

MD 20892–5452, (301) 451–3638, 

charlene.repique@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 15, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–21415 Filed 9–18–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Clinical Trials and Translational 

Research Advisory Committee. 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public. Individuals who plan to 

attend in-person or view the virtual 

meeting and need special assistance or 

other reasonable accommodations, 

should notify the Contact Person listed 

below in advance of the meeting. The 

meeting can be accessed from the NIH 

Videocast at the following link: https:// 

videocast.nih.gov/. 

Name of Committee: National Cancer 

Institute Clinical Trials and Translational 

Research Advisory Committee. 

Date: November 6, 2024. 

Time: 8:30 a.m. to 3:00 p.m. 

Agenda: Strategic Discussion of NCI’s 

Clinical and Translational Research 

Programs. 

Place: National Cancer Institute, 9609 

Medical Center Drive, East Wing, Conference 

Room TE406/408/410, Rockville, MD 20850 

(In Person and Virtual Meeting). 

Contact Person: Sheila A. Prindiville, M.D., 

M.P.H., Director, Coordinating Center for 

Clinical Trials, National Cancer Institute, 

National Institutes of Health, 9609 Medical 

Center Drive, Room 6W136, Rockville, MD 

20850, 240–276–6173, prindivs@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NCI-Shady Grove campus. All 

visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/ctac/ctac.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 13, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–21363 Filed 9–18–24; 8:45 am] 

BILLING CODE 4140–01–P 


lotter on DSK11XQN23PROD with NOTICES1